Document:

EX-4.7

 Exhibit 4.7 

FORM 51-102F3 

MATERIAL CHANGE REPORT 
  

	Item 1:	Name and Address of Company 

 Zymeworks Inc. (“Zymeworks” or the
“Company”) 
 1385 West 8th Avenue, Suite 540 

Vancouver, BC, Canada 
 V6H 3V9

  

	Item 2:	Date of Material Change 

 March 14, 2018 

 

	Item 3:	News Release 

 A news release announcing the material change was disseminated through
the facilities of Business Wire on March 14, 2018, and a copy was filed on the Company’s profile at www.sedar.com. 
  

	Item 4:	Summary of Material Change 

 On March 14, 2018, Zymeworks announced that ZW49 is
the first product candidate selected for clinical development utilizing the ZymeLinkTM antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics. 

 

	Item 5:	Full Description of Material Change 

 5.1 Full Description of Material Change

 On March 14, 2018, Zymeworks announced that ZW49 is the first product candidate selected for clinical development utilizing the
ZymeLinkTM antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics. ZW49 was developed by leveraging ZymeLink in combination with Zymeworks’ flagship AzymetricTM bispecific
platform. The Company expects to file an Investigational New Drug (IND) application this year in order to begin clinical trials with ZW49 for patients with HER2-expressing cancers. 

ZW49 is a novel bispecific ADC targeting two distinct domains of the HER2 receptor resulting in enhanced internalization and delivery of its
proprietary ZymeLink cytotoxic payload. ADCs incorporating ZymeLink have demonstrated a greater therapeutic window (range of doses that are both efficacious and tolerable) in preclinical testing than those incorporating the commonly used ADC
payloads DM1 or MMAE. As a result, ZW49 exhibited superior activity when assessed against other approved HER2-targeted therapies and Zymeworks’ previous internal ADC candidate, ZW33. Consequently, the Company will advance ZW49 in lieu of ZW33.
Preclinical data on ZW49 and more generally on the ZymeLink ADC platform will be presented at the annual meeting of the American Association for Cancer Research to be held April 2018 in Chicago. Abstracts for these preclinical data were published on
March 14, 2018. 

 Zymeworks, whose protein engineering expertise and resulting therapeutic platforms have resulted
in a network of global biopharmaceutical partners, is keenly focused on developing its own portfolio of product candidates. Its lead compound, ZW25, is currently being assessed in an adaptive Phase 1 clinical trial and has shown promising
single-agent anti-tumor activity in patients with heavily pretreated HER2 expressing cancers that have progressed after standard of care. Zymeworks continues to accelerate the development of ZW25 and is opening several new clinical sites across
North America in 2018. 
 About ADCs 

Antibody-drug conjugates are a class of anti-cancer therapies intended to precisely target tumor cells in order to avoid the significant
toxicities routinely associated with cancer treatments while simultaneously improving their efficacy. An ADC is an antibody connected, or conjugated, to a small molecule drug. It has three critical components: the antibody for targeting of specific
cells, the cytotoxin (or payload) being delivered to induce cancer cell death, and the linker, which connects the two components together. 

About ZW49 
 ZW49 is a
biparatopic (a bispecific antibody that can simultaneously bind two non-overlapping epitopes on a single target) anti-HER2 ADC based on the same framework as ZW25 but armed with the company’s proprietary
ZymeLinkTM cytotoxic (potent cancer-cell killing) payload. ZW49 may mediate its therapeutic effect through a combination of mechanisms, including: increased HER2 receptor-antibody clustering and internalization leading to toxin-mediated
cytotoxicity; dual HER2 signal blockade; increased binding and removal of HER2 protein from the cell surface; and potent effector function. 

5.2 Disclosure of Restructuring Transactions 

Not applicable. 
  

	Item 6:	Reliance on subsection 7.1(2) of National Instrument 51-102 

Not applicable. 
  

	Item 7:	Omitted Information 

 Not applicable. 

 

	Item 8:	Executive Officer 

 For further information, please contact Neil Klompas, Chief
Financial Officer of the Company at (604) 678-1388. 

  
 2 

	Item 9:	Date of Report 

 March 20, 2018 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 

This material change report includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
“forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this material change report include statements that relate to Zymeworks’
anticipated filing of an IND application, anticipated commencement of ZW49 clinical trials and anticipated clinical results, anticipated presentation of preclinical results at the American Association for Cancer Research annual meeting, its
strategies to develop ZW49, ZW49’s potential for best-in-class activity and tolerability, future development of ZW25, and other information that is not historical
information. When used herein, words such as “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential
to” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions, including assumptions regarding anticipated reporting of
preclinical data, ZW49’s activity compared to other molecules and the efficacy of ZW49. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its
expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the
factors described under “Risk Factors” in Zymeworks’ Annual Report on Form 10-K for its fiscal year ended December 31, 2017 (a copy of which may be obtained at www.sec.gov and
www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks’ current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future
results, events, levels of activity, performance or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish or revise any forward-looking statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated events, except as may be required by law. 

  
 3EX-4.8

 Exhibit 4.8 

FORM 51-102F3 

MATERIAL CHANGE REPORT 
  

	Item 1:	Name and Address of Company 

 Zymeworks Inc. (“Zymeworks” or the
“Company”) 
 1385 West 8th Avenue, Suite 540 

Vancouver, BC, Canada 
 V6H 3V9

  

	Item 2:	Date of Material Change 

 April 17, 2018 

 

	Item 3:	News Release 

 A news release announcing the material change was disseminated through
the facilities of Business Wire on April 17, 2018, and a copy was filed on the Company’s profile at www.sedar.com. 
  

	Item 4:	Summary of Material Change 

 On April 17, 2018, Zymeworks presented preclinical
data on ZW49, its lead bispecific antibody-drug conjugate candidate (ADC) and its ZymeLink ADC platform. 
  

	Item 5:	Full Description of Material Change 

 5.1 Full Description of Material Change

 On April 17, 2018, Zymeworks presented preclinical data on ZW49, its lead bispecific antibody-drug conjugate candidate (ADC) and
its ZymeLink ADC platform. As previously reported, Zymeworks expects to file an Investigational New Drug (IND) application this year in order to begin clinical trials with ZW49 for patients with HER2-expressing cancers. 

Abstract Number: 3914; ZW49, A HER2 Targeted Biparatopic Antibody Drug Conjugate for the Treatment of HER2 Expressing Cancers 

ZW49, which incorporates Zymeworks’ AzymetricTM bispecific and ZymeLinkTM ADC technology platforms, was shown to be active and
well tolerated in a series of preclinical studies. The unique biparatopic (ability to simultaneously bind two distinct locations on a single target) properties of ZW49 enable highly efficient delivery of its cancer cell killing payload while its
ZymeLink-enhanced tolerability allows higher doses to be administered leading to improved anti-tumor activity. In models of both high and low HER2-expressing cancers, administration of ZW49 resulted in complete regression of the tumors. Importantly,
ZW49 was well tolerated in preclinical safety studies at the same exposure levels that demonstrated efficacy in tumor models, without the toxicities generally associated with this class of ADC payloads. 

 Abstract Number: 3912; Towards Development of Next Generation Biparatopic ADCs Using a Novel
Linker-Toxin with Expanded Therapeutic Window 
 Many ADCs in development ultimately fail to demonstrate efficacy in clinical testing
due to dose-limiting toxicities. Zymeworks’ approach to ADC development is focused on efficient payload delivery and improving tolerability to enable greater exposures at the tumor rather than the conventional approach of solely increasing ADC
potency. Preclinical data demonstrate that ZymeLink improved the tolerability of ADCs against four known clinical targets compared to the corresponding ADC platforms used in clinical trials. This enabled ZymeLink ADC exposures of at least seven-fold
higher than benchmark ADCs which translated to increased anti-tumor activity in preclinical models. Ongoing efforts are focused on evaluating biparatopic versions of these ZymeLink ADC candidates to expand the therapeutic window even further. 

About ZW49 
 ZW49 is a
biparatopic (a bispecific antibody that can simultaneously bind two non-overlapping epitopes on a single target) anti-HER2 ADC based on the same antibody framework as ZW25, Zymeworks’ lead clinical
candidate being evaluated in a Phase 1 study, but armed with the company’s proprietary ZymeLink cytotoxic (potent cancer-cell killing) payload. ZW49 may mediate its therapeutic effect through a combination of mechanisms, including: increased
HER2 receptor-antibody clustering and internalization leading to toxin-mediated cytotoxicity; increased binding and removal of HER2 protein from the cell surface; and potent effector function. 

About Antibody-Drug Conjugates 

Antibody-drug conjugates (ADC) are a class of anti-cancer therapies intended to precisely target tumor cells in order to avoid the
significant toxicities routinely associated with cancer treatments while simultaneously improving their efficacy. An ADC is an antibody that is connected, or conjugated, to a small molecule drug. It has three critical components: the antibody for
targeting of specific cells, the cytotoxin (or payload) being delivered to induce cancer cell death, and the linker, which connects the two components together. 

About the ZymeLinkTM Platform 

The ZymeLink platform is a modular suite of site-specific conjugation technologies, customizable linkers, and proprietary cytotoxic payloads
designed for the targeted delivery of therapeutics with optimal tolerability and efficacy. The ZymeLink platform is compatible with traditional antibodies and with the Azymetric platform and is intended to facilitate the development of
next-generation therapeutics. 

  
 2 

 About the AzymetricTM Platform 

The Azymetric platform enables the transformation of monospecific antibodies into bispecific antibodies, giving them the ability to
simultaneously bind two different targets. AzymetricTM bispecific technology enables the development of multifunctional biotherapeutics that can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering
degradation, and increase tumor-specific targeting. These features are intended to enhance efficacy while reducing toxicities and the potential for drug-resistance. Azymetric bispecifics have been engineered to retain the desirable drug-like
qualities of naturally occurring antibodies, including low immunogenicity, long half-life and high stability. In addition, they are compatible with standard manufacturing processes with high yields and purity, potentially significantly reducing drug
development costs and timelines. 
 5.2 Disclosure of Restructuring Transactions 

Not applicable. 
  

	Item 6:	Reliance on subsection 7.1(2) of National Instrument 51-102 

Not applicable. 
  

	Item 7:	Omitted Information 

 Not applicable. 

 

	Item 8:	Executive Officer 

 For further information, please contact Neil Klompas, Chief
Financial Officer of the Company at (604) 678-1388. 
  

	Item 9:	Date of Report 

 April 17, 2018 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 

This material change report includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this material change report include, but are not limited to, statements that
relate to Zymeworks’ anticipated filing of an IND application, anticipated commencement of ZW49 clinical trials and anticipated clinical results, future development of ADC candidates, the expectation that the ZymeLink platform will facilitate
the development of next-generation therapeutics, the potential for the Azymetric platform to reduce drug development costs and timelines, future development of preclinical product candidates and discovery-stage programs in immuno-oncology and other
therapeutic areas, and other information that is not historical information. When used herein, words such as “anticipate”, “plan”, “expect”, “will”, “may”, “continue”, and similar
expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations
and beliefs, but they are inherently uncertain. Zymeworks may 

  
 3 

 
not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from 

those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors
described under “Risk Factors” in Zymeworks’ Annual Report on Form 10-K for its fiscal year ended December 31, 2017 (a copy of which may be obtained at www.sec.gov and www.sedar.com).
Consequently, forward-looking statements should be regarded solely as Zymeworks’ current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events,
levels of activity, performance or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to
reflect the occurrences of unanticipated events, except as may be required by law. 

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]